Insertable heart monitor finds elusive atrial fibrillation after unexplained stroke

American Stroke Association Meeting Late-Breaking Science Report Abstract: LB11 (Hall E)

February 14, 2014 Categories: Scientific Conferences & Meetings, Stroke News

Study highlights:

  • An insertable cardiac monitor worn for six months was up to seven times more likely to detect an irregular heart rhythm (atrial fibrillation) than much briefer monitoring with traditional techniques in patients who had an unexplained stroke.
  • Detecting atrial fibrillation in such patients affects the choice of medicines they are given, which in turn impacts future stroke risk.
Embargoed until Noon PT/ 3 p.m. ET, Friday, Feb. 14, 2014
This news release is featured in an Embargoed Media Briefing at 8 a.m. PT Friday, Feb. 14.

SAN DIEGO, Feb. 14, 2014 – A small cardiac monitor implanted under the skin proved six to seven times more likely than standard monitoring methods to find an irregular heart rhythm that may have caused a patient’s stroke, according to a late-breaking science report presented at the American Stroke Association’s International Stroke Conference 2014.

As many as 30 percent of ischemic strokes – those caused by a clot in a blood vessel supplying the brain – have no identifiable cause. But one possible explanation is a type of irregular heart rhythm called atrial fibrillation, or AF. With atrial fibrillation, the heart’s upper chambers (atria) beat erratically and rapidly, slowing blood flow in the atria and promoting clot formations there. Stroke risk is about five times higher in people with atrial fibrillation.

“Atrial fibrillation can be difficult to detect due to its sometimes intermittent nature, and the fact that it isn’t always accompanied by symptoms,” said Richard A. Bernstein, M.D., Ph.D., an author of the new study and professor of neurology at Northwestern University’s Feinberg School of Medicine in Chicago. “For a patient who has had an unexplained stroke, it’s really important to determine if they have AF, because left untreated, it could result in a second and even more devastating stroke.”

The new study, called CRYSTAL-AF (CRYptogenic STroke And UnderLying Atrial Fibrillation), included 441 patients who had an unexplained stroke. All had at least 24 hours of standard cardiac monitoring within 90 days of the stroke, and half were tracked with an insertable monitor (the Reveal® XT by Medtronic) which can provide data continuously for up to three years.

Six months later, atrial fibrillation had been found in 8.9 percent of patients with an insertable monitor, versus 1.4 percent of those who had standard testing. A year later, the condition had been detected in 12.4 percent of patients with the insertable monitor, compared with 2 percent of the others. After three years, that gap was 30 percent with the insertable monitor, versus 3 percent for standard testing.

The study was conducted in 55 centers in the United States, Canada and Europe.  Limitations of the research include variation in methods of standard cardiac monitoring in the control arm, due to different local practices, he said.

Most people who have a stroke caused by a blood clot are given aspirin or similar drugs, such as clopidogrel, to prevent another stroke, said Bernstein, who is also director of the Stroke Program at Northwestern Memorial Hospital. But in patients with atrial fibrillation, anticoagulants, such as warfarin, or the newer anticoagulants, have been found much more effective at preventing stroke. Anticoagulants aren’t routinely given in the absence of atrial fibrillation because they can be riskier and more inconvenient for patients.

“Finding AF after a stroke changes therapy from the aspirin class of drugs, which are not very effective in AF, to anticoagulants,” he said. Among patients in the study found to have AF, oral anticoagulants were prescribed for 97 percent of cases, the researchers reported.

An insertable cardiac monitor resembles a USB flash drive and has two electrodes to monitor heart rhythm. It can detect various kinds of heart irregularities and stores a log of events that indicates when and for how long each event occurred, and what was the heart rate.

The device is slipped under the skin of the chest via a small incision, using local anesthetic in a brief outpatient procedure. The monitor does not touch the heart.

The benefits of the insertable device far outweigh risks, Bernstein said, noting just 2.4 percent of the devices had to be removed in the study because of complications, and the patients had no long-term problems. “On the other hand, if a stroke patient has AF that hasn’t been caught; they could be at very high risk of another potentially disabling stroke because they aren’t on the right medication.”

However, the study did not have enough participants to see whether there was a difference between the two groups in rates of subsequent stroke. Stroke guidelines currently call for only 24-hour monitoring. The new study suggests long-term continuous monitoring may uncover more AF in patients with unexplained stroke, and can be useful if traditional monitoring fails.

Co-authors are Vincenzo Di Lazzaro, M.D.; Marilyn Mollman Rymer, M.D.; Hans-Christoph Diener, M.D., Ph.D.; Tommaso Sanna, M.D.; Johannes Brachmann, M.D., Ph.D.; Rod S. Passman, M.D., M.S.C.E.; Carlos Morillo, M.D.; Vincent Thjis, M.D.; Tyson Rogers, M.S.; Frank Beckers, Ph.D.; and Katherine Lindborg, Ph.D. Author disclosures are on the abstract.

Device manufacturer Medtronic funded the study.

Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.  The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content.  Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

###

Note: Actual presentation is 12:35 p.m. PT, Friday, Feb. 14, 2014 in Hall E.

ASA News Media in Dallas: (214) 706-1173
ASA News Media Office, Feb. 11-14, 2014
at the San Diego Convention Center: (619) 525-6204
For Public Inquiries:  (800) AHA-USA1 (242-8721)

 


  • Share